Clinical Trial Update: A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of a 6-month formulation of triptorelin in pediatric patients with Central Precocious Puberty has completed, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• Triptorelin (triptorelin)

Snippet

Sponsor: Ipsen | Conditions: Central Precocious Puberty | Phase 3 | Status: COMPLETED | Results posted: 2024-05-28